Articles

Atlanta, GA—Immune checkpoint inhibitors represent a tremendous advance in the treatment of several types of cancers. Although approximately 20% to 25% of patients will have durable responses with these agents, it has been challenging to find biomarkers to identify who these patients are. Read More ›

$Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation$

Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation

By Phoebe Starr

Leukemia

TON - June 2019, Vol 12, No 3

Atlanta, GA—Treatment with gilteritinib (Xospata) significantly improved overall survival (OS) with less toxicity compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and FLT3 mutation, according to the final results of ADMIRAL, a phase 3 clinical trial presented at the 2019 American Association for Cancer Research meeting. Read More ›

Considerations in Patient Navigation: Insights from an ONS Panel Discussion

By Adam Buffery

ONS

TON - June 2019, Vol 12, No 3

Anaheim, CA—Although nurse navigation is a relatively new concept in healthcare, a growing number of organizations are launching navigation programs that provide patients with valuable services as they go through the many stages of their cancer journey. A panel of nurse navigators and healthcare professionals convened at the Oncology Nursing Society (ONS) 44th Annual Conference to discuss key aspects of patient navigation, and give attendees the opportunity to ask questions and learn how navigators perform their roles and collaborate with other oncology nurses and members of the cancer care team to improve patient outcomes. Read More ›

Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types

By Phoebe Starr

Emerging Therapies

TON - June 2019, Vol 12, No 3

Atlanta, GA—Preclinical and clinical data support the potential for the investigational novel tyrosine kinase inhibitor (TKI) infigratinib for the treatment of different FGFR-driven tumor types, according to Sameek Roychowdhury, MD, PhD, Associate Professor, Medical Oncology, The Ohio State University, Columbus, who presented a poster with the preclinical results at the 2019 American Association for Cancer Research (AACR) meeting. Read More ›

$Umbralisib Shows Encouraging Results in Relapsed or Refractory Marginal-Zone Lymphoma$

Umbralisib Shows Encouraging Results in Relapsed or Refractory Marginal-Zone Lymphoma

By Phoebe Starr

Lymphoma

TON - June 2019, Vol 12, No 3

Atlanta, GA—The investigational PI3K inhibitor umbralisib had encouraging activity as monotherapy in patients with relapsed or refractory marginal-zone lymphoma in an analysis of the phase 2 UNITY-NHL trial. Interim results were presented at the 2019 American Association for Cancer Research (AACR) meeting. Read More ›

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

By Yvette Florio Lane

FDA Updates, In the News

Web Exclusives

On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation. Read More ›

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

FDA Updates

2019 Fourth Annual Oncology Guide to New FDA Approvals

The Lynx Group is pleased to bring you the Fourth Annual Oncology Guide to New FDA Approvals. The goal of this Guide is to offer oncologists, pharmacists, oncology nurses, and other healthcare stakeholders a comprehensive overview of new drugs approved by the US Food and Drug administration (FDA) in 2018 for the treatment of different types of cancer, including hematologic and oncologic malignancies. This practical tool offers a quick, evidence-based resource for hematology/oncology professionals to guide their medication-related decision-making and help ensure the administration of recent medicines for appropriate patients. Read More ›

New Indications Approved by the FDA in 2018 for Oncology Drugs

By Dalia Buffery, MA, ABD

FDA Updates

2019 Fourth Annual Oncology Guide to New FDA Approvals